UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 11, 2017
Insys Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-35902 | 51-0327886 |
(State of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
1333 South Spectrum Blvd, Suite 100
Chandler, Arizona 85286
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (480) 500-3127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 11, 2017, Insys Therapeutics, Inc. (the “Company”) accepted the resignation of Dr. Santosh Vetticaden, the interim Chief Executive Officer and Chief Medical Officer of Insys Therapeutics, Inc., whose employment will be terminated on April 28, 2017. Pursuant to the Current Report on Form 8-K previously filed with the Securities and Exchange Commission on March 27, 2017, the Company previously announced that, effective April 17, 2017, Saeed Motahari is the Company’s President and Chief Executive Officer and appointed as a member of the Company’s Board of Directors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 17, 2017 | Insys Therapeutics, Inc. |
| | |
| By: | /s/ Darryl S. Baker |
| | Darryl S. Baker |
| | Chief Financial Officer |
